Published Data in Hepatocellular Carcinoma

Over 140 peer reviewed publications have assessed the use of SIR-Spheres® Y-90 resin microspheres for HCC.

In addition to the RCTs outlined on previous pages, other studies have demonstrated efficacy and safety of SIR-Spheres Y-90 resin microspheres for patients with HCC. One of these studies showed a significantly increased mOS, in the first-line setting, of 8 months compared with matched controls receiving active treatment or supportive care in patients with unresectable advanced HCC.1

A large retrospective multicentre analysis of SIR-Spheres Y-90 resin microspheres in HCC included first-line and second-line treatment in 325 patients with advanced HCC (ENRY trial).2 All patients received SIR-Spheres Y-90 resin microspheres, and the authors noted the following:

  • Survival outcomes compared favourably with transarterial chemoembolisation (TACE)/transarterial embolisation (TAE) for unresectable patients in Barcelona Clinic Liver Cancer (BCLC) stages A and B.
  • Benefits of SIR-Spheres Y-90 resin microspheres treatment were particularly favourable for patients with intermediate, BCLC stage B disease who were poor candidates for TACE or had failed TACE/TAE.
  • SIR-Spheres Y-90 resin microspheres also showed positive results in patients with advanced stage (BCLC stage C) disease, particularly those with portal vein thrombosis (PVT).

Importantly, OS benefits are suggested with first-line or second-line use of SIR-Spheres Y-90 resin microspheres, irrespective of patient age, presence or absence of PVT, and whether or not the patient has had a previous procedure.2-5

An additional benefit of SIR-Spheres Y-90 resin microspheres is down-staging HCC to potentially curative resection and bridging some patients to transplant.3,4,6,7 These effects can reduce the burden of the disease on the patient, and with down-staging to allow for subsequent curative treatment, the burden on the healthcare systems can be reduced in the longer term.

1 D'Avola D et al.  Hepatogastroenterology 2009; 56: 1683-8.

2 Sangro B et al.  Hepatology 2011; 54: 868-78.
3 Inarrairaegui M et al.  Int J Radiat Oncol Biol Phys 2010; 77: 1441-8.
4 Lau WY et al.  Int J Radiat Oncol Biol Phys 1998; 40: 583-92.
5 Golfieri R et al.  J Hepatol 2013; 59: 753-61.
6 Gramenzi A et al.  Liver Int 2015; 35: 1036-47.
7 Ettorre GM et al.  World J Surg 2017; 41: 241-9.

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.



This content is intended for healthcare professionals only

By clicking "Yes" you are confirming that you are a healthcare professional. If you are not a healthcare professional, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage